Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | S100A4 | P26447 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29617011 | 1.00 | ALDH1A1 (0.52) | ALDH1A1HIF1ACYP1A2TDP1KMT2A | |
| SCHEMBL12982928 | 0.86 | ALDH1A1 (0.49) | ALDH1A1HIF1ACYP1A2TDP1KMT2A | |
| SCHEMBL30885438 | 0.86 | ALDH1A1 (0.49) | ALDH1A1HIF1ACYP1A2TDP1KMT2A | |
| SCHEMBL29471963 | 0.85 | ALDH1A1 (0.56) | ALDH1A1HIF1ACYP1A2TDP1KMT2A | |
| SCHEMBL830636 | 0.85 | ALDH1A1 (0.56) | ALDH1A1HIF1ACYP1A2TDP1KMT2A | |
| SCHEMBL8092845 | 0.83 | ALDH1A1 (0.47) | ALDH1A1HIF1ACYP1A2TDP1KMT2A | |
| SCHEMBL16207595 | 0.83 | ALDH1A1 (0.53) | ALDH1A1HIF1ACYP1A2TDP1KMT2A | |
| SCHEMBL17083672 | 0.83 | ALDH1A1 (0.53) | ALDH1A1HIF1ACYP1A2TDP1KMT2A | |
| SCHEMBL260864 | 0.82 | CYP1A2 (0.47) | ALDH1A1HIF1ACYP1A2TDP1KMT2A | |
| SCHEMBL29368452 | 0.82 | CYP1A2 (0.47) | ALDH1A1HIF1ACYP1A2TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125376-A1 | IRREVERSIBLE INACTIVATORS TARGETING ARAF/MEK COMPLEXES | GERO THOMAS (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4727652-A1 | (HETERO)ARYL-SULFONAMIDE COMPOUNDS AS MODULATORS OF GPR35 | ThirtyFiveBio Limited (GB) | 2026-04-22 | — | — | EP | disclosed |
| US-12606564-B2 | Adenosine receptor antagonist compounds | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2026-04-21 | — | — | US | disclosed |
| EP-4676926-A1 | BICYCLIC HETEROARYL COMPOUNDS FOR USE AS GPR35 MODULATORS | ThirtyFiveBio Limited (GB) | 2026-01-14 | — | — | EP | disclosed |
| EP-4646402-A1 | GPR35 MODULATORS | ThirtyFiveBio Limited (GB) | 2025-11-12 | — | — | EP | disclosed |
| US-12459957-B2 | Therapeutic compounds and methods | GENENTECH, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4638433-A1 | NAMPT MODULATORS | Cytokinetics, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4598521-A2 | IRREVERSIBLE INACTIVATORS TARGETING ARAF/MEK COMPLEXES | Dana-Farber Cancer Institute, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250109142-A1 | THERAPEUTIC COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2025-04-03 | — | — | US | disclosed |
| WO-2025059562-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AND METHODS OF TREATING DISEASE USING SAME | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003099805-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| EP-0350113-B1 | Liquid crystalline polyesters | AKZO NOBEL NV (NL) | 1995-01-25 | — | — | EP | disclosed |
| US-4959448-A | Optical waveguides | AKZO N.V. (NL) | 1990-09-25 | — | — | US | disclosed |
| EP-0350113-A1 | Liquid crystalline polyesters | Akzo Nobel N.V. (NL) | 1990-01-10 | — | — | EP | disclosed |
| US-4486355-A | INSECTICIDES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-12-04 | — | — | US | disclosed |
| US-4385070-A | CYCLOPROPANE DERIVATIVES AS INSECTICIDES | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1983-05-24 | — | — | US | disclosed |
| EP-0016513-B1 | ESTERS OF HALOGENATED SUBSTITUTED CYCLOPROPANOIC ACIDS, THEIR PREPARATION AND USE AS INSECTICIDES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-06-23 | — | — | EP | disclosed |
| EP-0032121-A2 | Substituted tetrafluorobenzyl alcohols and halides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-07-15 | — | — | EP | disclosed |
| EP-0016513-A2 | Esters of halogenated substituted cyclopropanoic acids, their preparation and use as insecticides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1980-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | ALDH1A1 2779/4885HIF1A 2979/4885CYP1A2 1529/4885 |
| US-20260125376-A1 | IRREVERSIBLE INACTIVATORS TARGETING ARAF/MEK COMPLEXES | ARAF, BRAF, RAF1 | ALDH1A1 1037/4885HIF1A 1569/4885CYP1A2 2713/4885 |
| US-12606564-B2 | Adenosine receptor antagonist compounds | ADORA2A, ADORA1, ADORA2B | ALDH1A1 610/4885HIF1A 435/4885CYP1A2 2207/4885 |
| US-20250109142-A1 | THERAPEUTIC COMPOUNDS AND METHODS | PCK1, SLC5A1, PFKFB1 | ALDH1A1 345/4885HIF1A 378/4885CYP1A2 680/4885 |
| US-12459957-B2 | Therapeutic compounds and methods | PCK1, SLC5A1, PFKFB1 | ALDH1A1 345/4885HIF1A 378/4885CYP1A2 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.